A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease

Supportive Care in Cancer

Volumn 24, Issue 7, 2016, Pages 3069-3076

  Hardy, Janet ^a   Randall, Clare ^b   Pinkerton, Eve ^a   Flatley, Christopher ^a   Gibbons, Kristen ^a   Allan, Simon ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Arohanui Hospice   (New Zealand)

Author keywords

Anxiety; Dyspnoea; Intranasal; Midazolam

Indexed keywords

MIDAZOLAM; NOSE SPRAY; PLACEBO; HYPNOTIC SEDATIVE AGENT;

ADULT; AGED; ANXIETY; ANXIETY ASSESSMENT; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FUNCTIONAL DISEASE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LACRIMATION DISORDER; LIFE LIMITING DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PARANASAL SINUS DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; TASTE DISORDER; TERMINAL DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; DRUG DELIVERY SYSTEM; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGY;

ADMINISTRATION, INTRANASAL; AGED; ANXIETY; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; DYSPNEA; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; MIDDLE AGED; PILOT PROJECTS;

EID: 84971350880     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-016-3125-2     Document Type: Article

References (34)

1. Gysels M, Bausewein C, Higginson IJ (2007) Experiences of breathlessness: a systematic review of the qualitative literature. Pall Support Care 5:281–302
2. Clemens KE, Klaschik E (2007) Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative patients. J Pain Sympt Manag 33(4):473–481
3. Solano JP, Gomes B, Higginson IJ (2006) A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Sympt Manag 31(1):58–69
4. Booth S, Moosavi SH, Higginson IJ (2008) The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nature Clin Pract Onc. (2):90–100
5. Navigante AH, Leandro CA, Cerchietti ME, Castro MA, Lutteral MA, Cabalar ME (2006) Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnoea perception in patients with advanced cancer. J Pain Sympt Manag 31(1):38–47
6. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A (2003) Bui C (2003) randomised, double blind, placebo controlled crossover trial of sustained release morphine for management of refractory dyspnoea. BMJ 327:523–528
7. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C (2010) Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database of Systematic Reviews. (1):CD007354. DOI:10.1002/14651858.CD007354.pub2
8. Ekstrom MP, Bornefalk-Hermansson A, Abernethy A, Currow D (2014) Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 348:g445. doi:10.1136/bmj.g445
9. Datasheet www.medsafe.govt.nz. Accessed 21 March 2009
10. Harbord MG, Kyrkou NE, Kyrkou MR, Kay D, Coulthard K (2004) Use of intranasal midazolam to treat acute seizures in paediatric community. J Paed Child Health 40(9/10):556–558
11. Klein-Kremmer A, Goldman RD (2007) Intranasal midazolam for treatment of seizures in children in the emergency setting Israeli. J Emerg Med 7(2):31–35
12. Kyrkou M, Harbord M, Kyrkou N, Kay D, Coulthard K (2006) Community use of intranasal midazolam for managing prolonged seizures. J Intell Devel Dis 31(3):131–138
13. Bhattacharyya M, Kalra V, Gulati S (2006) Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol 34:355–359
14. Wolfe TR, Macfarlane TC (2006) Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med 24:343–346
15. Ljungman G, Kreuger A, Andreasson S, Gordh T, Sorensen S (2000) Midazolam nasal spray reduces procedural anxiety in children. Paediatrics 105(1):73–78
16. Gilchrist F, Cairns AM, Leitch JA (2007) The use of intranasal midazolam in the treatment of paediatric dental patients. Anaesthesia 62:1262–1265
17. Henderson M, MacGregor E, Sykes N, Hotopf M (2006) The use of benzodiazepines in palliative care. Palliat Med 20:407–412
18. Cachia E, Ahmedzai SH (2008) Breathlessness in cancer patients. Eur J Cancer 44:1116–1123
19. Knoester PD, Jonker DM, van der Hoeven RTM, Vermeij TAC, Edelbroek PM, Brekelmans GJ, et al. (2002) Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol 53:501–507
20. Wermeling DP, Record KA, Archer SM, Rudy AC (2009) A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res 83:124–132
21. Randall CJ, Quinn B, Allan SG (2008) Intra-nasal midazolam as an adjunct to management of breathlessness in palliative care. Abstract, Hospice New Zealand Conference, Palmerston North
22. Dorman S, Jolley C, Abernethy A, et al. (2009) Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Medicine 23:213–227
23. Abernethy AP, Shelby-James T, Fazekas B, Woods D, Currow DC (2005) The Australian-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Palliative Care 4:7
24. Heyse-Moore LH (2003) On dyspnoea in advanced cancer. Southhampton University, Southhampton,UK
25. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370
26. Lipman RS (1982) Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 18(4):69–77
27. Tanaka K, Akechi T, Okuyama T, et al. (2008) Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Brit J Cancer 82:800–805
28. Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, V3.0, March 31 2003, published Aug 9 2006
29. Piantadosi S (2005) Clinical trials. A methodological perspective, 2nd edn. John Wiley & Sons, New Jersey
30. StataCorp (2013) Stata statistical software: release 13. StataCorp LP, College Station, TX
31. Hrobjartsson A and Gotzsche PC (2010) Placebo interventions for all clinical conditions, Cochrane Database Systematic Reviews (1):CD003974. doi:10.1002/14651858.CD003974.pubs
32. Farrar J, Young J, LaMoreaux L, Werth J, Poole M (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158
33. Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC (2013) Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manag 46:957–963
34. Ekstrom M, Abernethy A, Currow D (2015) The management of chronic breathlessness in patients with advanced and terminal illness. BMJ 349:g7617